Experience with abatacept in refractory lupus nephritis
We present two cases of lupus nephritis patients in whom addition of abatacept resulted in complete remission of the renal disease. The first case described a 49-year-old male with class IV lupus nephritis with nephrotic range proteinuria and high immunological activity refractory to conventional treatment with cyclophosphamide and corticosteroids and multitarget therapy with tacrolimus, mycophenolate mofetil and prednisone. Several biological therapies (rituximab, belimumab and tocilizumab) were unsuccessfully tried, so that abatacept was added to his background multitarget therapy showing complete clinical response. The ...
Source: Rheumatology International - November 9, 2023 Category: Rheumatology Source Type: research
Towards the Lowest Efficacious Dose (ToLEDo): Results of a Multicenter Non ‐Inferiority Randomized Open‐Label Controlled Trial Assessing Tocilizumab or Abatacept Injection Spacing in Rheumatoid Arthritis in Remission
ConclusionsThe ToLEDo trial failed to demonstrate NI for the proposed ABA or TCZ tapering strategy. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - November 9, 2023 Category: Rheumatology Authors: Joanna Kedra,
Philippe Dieud é,
Caroline Giboin,
Hubert Marotte,
Carine Salliot,
Thierry Schaeverbeke,
Aleth Perdriger,
Martin Soubrier,
Jacques Morel,
Arnaud Constantin,
Emmanuelle Dernis,
Valérie Royant,
Jean‐Hugues Salmon,
Thao Pham,
Tags: Full Length Source Type: research
RA-ILD - new insights into disease burden from an international patient survey
Conclusion: Based on this patient survey, symptoms and management of RA-ILD are heterogenous and treatments are diverse. Future strategies must aim to improve management approaches in this debilitating organ manifestation of RA. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Kreuter, M., Antoniou, K., Avouac, J., Bendstrup, E., Brown(+), G., Castellvi, I., Castaneda, S., Cottin, V., Crestani, B., Dieude, P., Galvin, L., Geissler, K., Green, C., Jacob, J., Jones, S., Krause, A., Long, P., Maurer, B., Mosor, E., Maher, T. M., P Tags: ILD/DPLD of known origin Source Type: research
Experience with abatacept in refractory lupus nephritis
We present two cases of lupus nephritis patients in whom addition of abatacept resulted in complete remission of the renal disease. The first case described a 49-year-old male with class IV lupus nephritis with nephrotic range proteinuria and high immunological activity refractory to conventional treatment with cyclophosphamide and corticosteroids and multitarget therapy with tacrolimus, mycophenolate mofetil and prednisone. Several biological therapies (rituximab, belimumab and tocilizumab) were unsuccessfully tried, so that abatacept was added to his background multitarget therapy showing complete clinical response. The ...
Source: Rheumatology International - October 19, 2023 Category: Rheumatology Source Type: research
Generation-Dependent Retention Rates and Reasons for Discontinuation of Molecular Targeted Therapies in Patients with Rheumatoid Arthritis: From FIRST Registry
ConclusionsThe study highlights the need to consider different age groups separately in elderly RA care. Among patients aged 75 years and older, abatacept and anti-IL-6R antibodies showed the highest continuation rates, suggesting their potential suitability and efficacy for this specific age cohort. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - October 19, 2023 Category: Rheumatology Source Type: research
Methotrexate safety and efficacy in combination therapies in patients with early rheumatoid arthritis: a post ‐hoc analysis of a randomized controlled trial (NORD‐STAR)
ConclusionMethotrexate was generally well tolerated in combination therapies, but adverse events were a limiting factor in receiving the target dose of 25 mg/week, and these were more frequent in combination with tocilizumab versus active conventional treatment. On the other hand, methotrexate dose reductions were not associated with decreased CDAI remission rates within any of the four treatment combinations at 24 weeks.This article is protected by copyright. All rights reserved. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - October 17, 2023 Category: Rheumatology Authors: Kristina Lend,
Frieda A Koopman,
Jon Lampa,
Gerrit Jansen,
Merete Hetland L,
Till Uhlig,
Dan Nordstr öm,
Michael Nurmohamed,
Bjorn Gudbjornsson,
Anna Rudin,
Mikkel Østergaard,
Marte S Heiberg,
Tuulikki Sokka‐Isler,
Kim Hørslev‐Petersen Tags: Full Length Source Type: research
Therapeutic Effects of Treating COVID-19 Vaccine-Induced Anti-TIF1- γ-Positive Dermatomyositis
We present the case of a 90-year-old Taiwanese female who was newly diagnosed with anti-transcription intermediary factor 1-gamma (anti-TIF1-γ)-positive dermatomyositis (DM) after receiving a second dose of the AstraZeneca COVID-19 vaccine. Under treatment with prednisolone and monoclonal antibody therapy of abatacept, her skin lesions improved, and her muscle power increased. The serum creatinine phosphokinase level decreased from 4858 to 220 U/L, and the anti-TIF1-γ antibody titer decreased from 202 to 99. Flow cytometry data showed an increase in T cells, while NK cells, B cells (CD19), and plasma blasts all decreased...
Source: Medicina (Kaunas) - September 28, 2023 Category: Universities & Medical Training Authors: Chih-Feng Wu Wan-Ting Chen Yen-Lin Chen Feng-Cheng Liu Source Type: research
Therapeutic Effects of Treating COVID-19 Vaccine-Induced Anti-TIF1- γ-Positive Dermatomyositis
We present the case of a 90-year-old Taiwanese female who was newly diagnosed with anti-transcription intermediary factor 1-gamma (anti-TIF1-γ)-positive dermatomyositis (DM) after receiving a second dose of the AstraZeneca COVID-19 vaccine. Under treatment with prednisolone and monoclonal antibody therapy of abatacept, her skin lesions improved, and her muscle power increased. The serum creatinine phosphokinase level decreased from 4858 to 220 U/L, and the anti-TIF1-γ antibody titer decreased from 202 to 99. Flow cytometry data showed an increase in T cells, while NK cells, B cells (CD19), and plasma blasts all decreased...
Source: Medicina (Kaunas) - September 28, 2023 Category: Universities & Medical Training Authors: Chih-Feng Wu Wan-Ting Chen Yen-Lin Chen Feng-Cheng Liu Source Type: research
Therapeutic Effects of Treating COVID-19 Vaccine-Induced Anti-TIF1- γ-Positive Dermatomyositis
We present the case of a 90-year-old Taiwanese female who was newly diagnosed with anti-transcription intermediary factor 1-gamma (anti-TIF1-γ)-positive dermatomyositis (DM) after receiving a second dose of the AstraZeneca COVID-19 vaccine. Under treatment with prednisolone and monoclonal antibody therapy of abatacept, her skin lesions improved, and her muscle power increased. The serum creatinine phosphokinase level decreased from 4858 to 220 U/L, and the anti-TIF1-γ antibody titer decreased from 202 to 99. Flow cytometry data showed an increase in T cells, while NK cells, B cells (CD19), and plasma blasts all decreased...
Source: Medicina (Kaunas) - September 28, 2023 Category: Universities & Medical Training Authors: Chih-Feng Wu Wan-Ting Chen Yen-Lin Chen Feng-Cheng Liu Source Type: research
Therapeutic Effects of Treating COVID-19 Vaccine-Induced Anti-TIF1- γ-Positive Dermatomyositis
We present the case of a 90-year-old Taiwanese female who was newly diagnosed with anti-transcription intermediary factor 1-gamma (anti-TIF1-γ)-positive dermatomyositis (DM) after receiving a second dose of the AstraZeneca COVID-19 vaccine. Under treatment with prednisolone and monoclonal antibody therapy of abatacept, her skin lesions improved, and her muscle power increased. The serum creatinine phosphokinase level decreased from 4858 to 220 U/L, and the anti-TIF1-γ antibody titer decreased from 202 to 99. Flow cytometry data showed an increase in T cells, while NK cells, B cells (CD19), and plasma blasts all decreased...
Source: Medicina (Kaunas) - September 28, 2023 Category: Universities & Medical Training Authors: Chih-Feng Wu Wan-Ting Chen Yen-Lin Chen Feng-Cheng Liu Source Type: research
Therapeutic Effects of Treating COVID-19 Vaccine-Induced Anti-TIF1- γ-Positive Dermatomyositis
We present the case of a 90-year-old Taiwanese female who was newly diagnosed with anti-transcription intermediary factor 1-gamma (anti-TIF1-γ)-positive dermatomyositis (DM) after receiving a second dose of the AstraZeneca COVID-19 vaccine. Under treatment with prednisolone and monoclonal antibody therapy of abatacept, her skin lesions improved, and her muscle power increased. The serum creatinine phosphokinase level decreased from 4858 to 220 U/L, and the anti-TIF1-γ antibody titer decreased from 202 to 99. Flow cytometry data showed an increase in T cells, while NK cells, B cells (CD19), and plasma blasts all decreased...
Source: Medicina (Kaunas) - September 28, 2023 Category: Universities & Medical Training Authors: Chih-Feng Wu Wan-Ting Chen Yen-Lin Chen Feng-Cheng Liu Source Type: research
Therapeutic Effects of Treating COVID-19 Vaccine-Induced Anti-TIF1- γ-Positive Dermatomyositis
We present the case of a 90-year-old Taiwanese female who was newly diagnosed with anti-transcription intermediary factor 1-gamma (anti-TIF1-γ)-positive dermatomyositis (DM) after receiving a second dose of the AstraZeneca COVID-19 vaccine. Under treatment with prednisolone and monoclonal antibody therapy of abatacept, her skin lesions improved, and her muscle power increased. The serum creatinine phosphokinase level decreased from 4858 to 220 U/L, and the anti-TIF1-γ antibody titer decreased from 202 to 99. Flow cytometry data showed an increase in T cells, while NK cells, B cells (CD19), and plasma blasts all decreased...
Source: Medicina (Kaunas) - September 28, 2023 Category: Universities & Medical Training Authors: Chih-Feng Wu Wan-Ting Chen Yen-Lin Chen Feng-Cheng Liu Source Type: research
